Qu Biologics
Qu Biologics is a Canada-based biotechnology firm that researches and develops immunotherapies for the treatment of cancer and chronic inflammatory diseases.
Business Model:
Revenue: $14.5M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Qu Biologics Information
Geographic Data
Address: 4475 Wayburne Drive
City: Burnaby
State: british columbia
Zip: V5G 4X4
Country: CA
Financial Info
Stage:
series unknown
Raised Last:
$12M
Raised Total:$23M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Qu Biologics is a Canada-based biotechnology firm that researches and develops immunotherapies for the treatment of cancer and chronic inflammatory diseases.
Contact Phone:
+16047341450
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2022 | Venture Round | $12M | 5/2018 | Equity | $48.8k | 12/2015 | Venture Round | $2.5M | 10/2022 | Grant | 1 | $6.7M |
National Research Council of Canada Industrial Research Assistance Program National Research Council of Canada Industrial Research Assistance Program National Research Council of Canada Industrial Research Assistance Program National Research Council of Canada Industrial Research Assistance Program |
11/2020 | Venture Round | 1 | - |
Neue Fund Harmonix Fund Neue Fund Harmonix Fund |
12/2020 | Debt | $8M | 10/2022 | Equity | $6.7M | 4/2016 | Equity | $3.1M | 9/2014 | Venture Round | $4.1M | 4/2016 | Venture Round | $4M | 11/2020 | Venture Round | 1 | - |
Neue Fund Neue Fund |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
